Chemotherapy News and Research

Latest Chemotherapy News and Research

Lapatinib-pazopanib combination therapy not beneficial for patients with inflammatory breast cancer

Inflammatory breast cancer is a very aggressive type of cancer associated with early metastasis and poor survival rates, and the prognosis is even worse for patients with tumors expressing the ErbB2 receptor. The ErbB2-inhibiting drug lapatinib can slow the spread of cancer cells in individuals with advanced breast cancer who have already tried other chemotherapy medications.

2 Jun 2012

Studies support diagnostic utility of molecular classification in difficult-to-diagnose metastatic cancer

bioTheranostics, Inc., developer of innovative oncology diagnostic tests and solution provider for metastatic cancer, today announced findings from two studies showing high diagnostic accuracy for CancerTYPE ID in determining the primary tumor site in high-grade, metastatic tumors. Results were reported at the 2012 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

2 Jun 2012

'Atzelberg Circle' researchers meet to advance hyperthermia as standard combination cancer therapy

BSD Medical Corporation, a developer and manufacturer of advanced medical systems that utilize heat therapy to treat cancer, announced today that a distinguished, international team of leading oncologists met in council while attending the May 2012 conference of the European Society for Radiotherapy and Oncology (ESTRO) in Barcelona, Spain.

2 Jun 2012

New medication proves effective in slowing the spread of metastatic prostate cancer

A new medication proved effective in slowing the spread of metastatic prostate cancer, while helping to maintain the quality of life, in patients with advanced disease. The phase 3 study was unblinded midway, allowing patients receiving the placebo to instead take the drug because of the favorable results.

2 Jun 2012

Agendia launches ColoPrint microarray-based 18-gene expression signature for colon cancer

Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced the launch of its ColoPrint microarray-based 18-gene expression signature for predicting the risk of distant recurrence for stage II colon cancer patients who have undergone surgery.

2 Jun 2012

Precision Therapeutics’ ChemoFx test feasible in cervical cancer

Precision Therapeutics announces the acceptance of a new abstract on the ChemoFx® in vitro drug response marker for publication in conjunction with the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting.

2 Jun 2012

HNC patients may be at increased risk for post-treatment side effects

New data from an Internet-based study show that patients with head and neck cancers (HNC) may be at risk for significant late effects after their treatment, but they're unlikely to discuss these and other survivorship care issues with their doctors.

2 Jun 2012

Liver metastases predicts shorter overall survival in men with mCRPC

Liver metastases predicts shorter overall survival in men with metastatic castration-refractory prostate cancer (mCRPC), according to data being presented at the 2012 American Society of Clinical Oncology Annual Meeting in Chicago.

2 Jun 2012

Inhibiting IRE1α-XBP1 pathway impacts survival of myeloma cells

Results published in Blood, the official journal of the American Society of Hematology, confirm that inhibition of the IRE1α-XBP1 pathway impacts the survival of myeloma cells, suggesting a promising therapeutic option in multiple myeloma.

2 Jun 2012

Montefiore experts available to discuss cancer research at 2012 ASCO meeting

Bringing together international experts with the latest technologies and pioneering research, Montefiore Einstein Center for Cancer Care, in collaboration with the National Cancer Institute-designated Albert Einstein Cancer Center, advances the front lines of prevention, diagnosis and treatment of rare and common cancers.

2 Jun 2012

Distinctive protein pathways in certain leukemia patients

Scientists at Rice University and the University of Texas MD Anderson Cancer Center have successfully profiled protein pathways found to be distinctive to leukemia patients with particular variants of the disease.

1 Jun 2012

Results from A.P. Pharma’s APF530 Phase 3 trial on CINV

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that an abstract analyzing a subset of efficacy results from its Phase 3 trial of APF530 has been published in conjunction with the American Society of Clinical Oncology's (ASCO) 2012 Annual Meeting.

1 Jun 2012

Viewpoints: Bishops' request for contraception exemption may push legal precedent; Maine's experiment on health care

43 Roman Catholic organizations have filed lawsuits challenging a ... regulation that requires employers or their health insurers to offer birth control coverage to workers. The plaintiffs say that complying with the regulation would violate their religious freedom.

1 Jun 2012

NCI, Tau Therapeutics open enrollment in mibefradil Phase Ib glioma trial

Tau Therapeutics LLC, a pharmaceutical company developing T-type calcium channel inhibitors for the treatment of solid tumors, announced today that it has opened enrollment for a Phase Ib clinical trial with the National Cancer Institute's Adult Brain Tumor Consortium (ABTC) using the company's first product candidate mibefradil.

1 Jun 2012

Data from Response Genetics' tests against cancer to be presented at ASCO 2012

Response Genetics, Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, announced today four presentations to be held during the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL from June 1 to June 5, 2012. Study results are based on the company's proprietary technology and approach.

31 May 2012

CTI announces results from PIX301 phase 3 trial of Pixuvri for NHL

Cell Therapeutics, Inc. today announced that results from its PIX301 phase 3 clinical trial of Pixuvri (pixantrone) have been published online in The Lancet Oncology.

31 May 2012

TAU researcher develops new antibodies to target and destroy cancer cells

Because cancer cells grow very quickly, chemotherapy is designed to target cells whose numbers grow rapidly. But this treatment comes with a heavy price - many healthy cells essential for body functions are also targeted and killed by the toxin. This dangerous side-effect has prompted researchers to seek better and more selective ways to kill cancer cells inside the body.

31 May 2012

Experimental drug shows promise for elderly chronic leukemia patients

The experimental drug ibrutinib is highly active and well tolerated in elderly, treatment-naive patients with chronic lymphocytic leukemia, US researchers report.

30 May 2012

Beyond chemotherapy to cure leukemia

The fight against cancer is not won in a single battle: long after a cancer has been beaten into remission, it can return. The reason for this is under debate, and much is unclear.

30 May 2012

Scientists show why leukemia often returns

The fight against cancer is not won in a single battle: Long after a cancer has been beaten into remission, it can return. The reason for this is under debate, and much is unclear. New research led by Weizmann Institute scientists shows that, at least for one type of blood cancer, the source of cancer recurrence is in a set of cells that do not proliferate as quickly as regular cancer cells, and thus able to survive chemotherapy.

30 May 2012